We research and develop biopharmaceutical products, including those based on our
patented DNA delivery technologies, for the prevention and treatment of serious
or life-threatening diseases.
We currently have four active, independent or partnered, development programs in
the area of infectious disease comprised of:
· An ongoing Phase 3 clinical trial of ASP0113 for prevention of
cytomegalovirus, or CMV, reactivation in hematopoietic stem cell
transplant recipients and an ongoing Phase 2 clinical trial of ASP0113 for
prevention of CMV infection in kidney transplant recipients, both in
collaboration with Astellas Pharma Inc., or Astellas. Astellas expects
enrollment in the Phase 3 clinical trial to be completed during the third
quarter of 2016.